A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Trial Profile

A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2017

At a glance

  • Drugs Ornithine phenylacetate (Primary) ; Ornithine phenylacetate (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jan 2017 Status changed from recruiting to completed, according to an Ocera Therapeutics media release.
    • 05 Jan 2017 Results published in an Ocera Therapeutics media release.
    • 19 Sep 2016 According to an Ocera Therapeutics media release, the company expects data from multi-dose regimen (Part 2) by end of the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top